Chatzizacharias NA, Rosich-Medina A, Dajani K, Harper S, Huguet E, Liau SS, Praseedom RK, Jah A. Surgical management of hepato-pancreatic metastasis from renal cell carcinoma. World J Gastrointest Oncol 2017; 9(2): 70-77 [PMID: PMC5314203 DOI: 10.4251/wjgo.v9.i2.70]
Corresponding Author of This Article
Asif Jah, Consultant, Department of HPB and Transplant Surgery, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridgeshire CB2 0QQ, United Kingdom. asif.jah@addenbrookes.nhs.uk
Research Domain of This Article
Surgery
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Feb 15, 2017; 9(2): 70-77 Published online Feb 15, 2017. doi: 10.4251/wjgo.v9.i2.70
Surgical management of hepato-pancreatic metastasis from renal cell carcinoma
Nikolaos A Chatzizacharias, Anais Rosich-Medina, Khaled Dajani, Simon Harper, Emmanuel Huguet, Siong S Liau, Raaj K Praseedom, Asif Jah
Nikolaos A Chatzizacharias, Anais Rosich-Medina, Khaled Dajani, Simon Harper, Emmanuel Huguet, Siong S Liau, Raaj K Praseedom, Asif Jah, Department of HPB and Transplant Surgery, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridgeshire CB2 0QQ, United Kingdom
Author contributions: All the authors contributed to the manuscript.
Institutional review board statement: The study was reviewed and approved by the Hepatopancreatobiliary Institutional Review Board.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent at the time of the operation prior to the study.
Conflict-of-interest statement: The authors declare no conflicts of interest regarding this manuscript.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at asif.jah@addenbrookes.nhs.uk. Participants’ consent was not obtained for data sharing but the presented data are anonymized with no risk of identification.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Asif Jah, Consultant, Department of HPB and Transplant Surgery, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridgeshire CB2 0QQ, United Kingdom. asif.jah@addenbrookes.nhs.uk
Telephone: +44-1223-257074 Fax: +44-1223-216015
Received: August 9, 2016 Peer-review started: August 10, 2016 First decision: September 12, 2016 Revised: October 16, 2016 Accepted: November 21, 2016 Article in press: November 22, 2016 Published online: February 15, 2017 Processing time: 189 Days and 22.4 Hours
Abstract
AIM
To investigate the outcomes of liver and pancreatic resections for renal cell carcinoma (RCC) metastatic disease.
METHODS
This is a retrospective, single centre review of liver and/or pancreatic resections for RCC metastases between January 2003 and December 2015. Descriptive statistical analysis and survival analysis using the Kaplan-Meier estimation were performed.
RESULTS
Thirteen patients had 7 pancreatic and 7 liver resections, with median follow-up 33 mo (range: 3-98). Postoperative complications were recorded in 5 cases, with no postoperative mortality. Three patients after hepatic and 5 after pancreatic resection developed recurrent disease. Median overall survival was 94 mo (range: 23-94) after liver and 98 mo (range: 3-98) after pancreatic resection. Disease-free survival was 10 mo (range 3-55) after liver and 28 mo (range 3-53) after pancreatic resection.
CONCLUSION
Our study shows that despite the high incidence of recurrence, long term survival can be achieved with resection of hepatic and pancreatic RCC metastases in selected cases and should be considered as a management option in patients with oligometastatic disease.
Core tip: The evidence on the role of surgery in management of renal cell carcinoma (RCC) metastatic disease to the liver and pancreas remains limited due to the rare nature of the disease. We have treated 13 patients in our institution, achieving median overall survival of 94 mo (range: 23-94) after liver and 98 mo (range: 3-98) after pancreatic resection. Disease-free survival was 10 mo (range: 3-55) after liver and 28 mo (range: 3-53) after pancreatic resection. Long term survival can be achieved with resection of hepatic and pancreatic RCC metastases in selected cases and should be considered in patients with oligometastatic disease.
